organization · Reporting owner

Versant Voyageurs I, L.P.

Disclosed activity across 2 companies

Tapewire entity: 87880
SEC CIK: 0001745960

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Black Diamond Therapeutics, Inc.BDTX · Entity 6669	10% owner	August 28, 2024	August 30, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Black Diamond Therapeutics, Inc.

Report date August 28, 2024 · Filed August 30, 2024

Jointly reported with Versant Venture Capital VI, L.P., Versant Voyageurs I Parallel, L.P., Versant Vantage I, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,726,341	Reported balance After 2024-08-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-08-28 · Sale · Disposed 221,600 · Balance 3,726,341 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,277,541	Reported balance Holding disclosure · report date 2024-08-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,277,541 F3: These shares are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I and may be deemed to share voting, investment and dispositive power over the shares held by Versant Voyageurs I. Versant Voyageurs I GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	380,942	Reported balance Holding disclosure · report date 2024-08-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 380,942 F4: These shares are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") is the general partner of Versant I Parallel and may be deemed to share voting, investment and dispositive power over the shares held by Versant I Parallel and disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	822,140	Reported balance Holding disclosure · report date 2024-08-28 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 822,140 F5: These shares are held of record by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP and each may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I. Each of Versant Vantage I GP-GP and Versant Vantage I GP LP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

F3: These shares are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I and may be deemed to share voting, investment and dispositive power over the shares held by Versant Voyageurs I. Versant Voyageurs I GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.

F4: These shares are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") is the general partner of Versant I Parallel and may be deemed to share voting, investment and dispositive power over the shares held by Versant I Parallel and disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein.

F5: These shares are held of record by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP and each may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I. Each of Versant Vantage I GP-GP and Versant Vantage I GP LP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHINOOK THERAPEUTICS, INC.

Report date April 04, 2022 · Filed April 06, 2022

Jointly reported with Versant Venture Capital VII, L.P., Versant Voyageurs I Parallel, L.P.

Section 16 reporting ended · disclosed 2022-04-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,913,070	Reported balance After 2022-04-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-04-04 · Other · Disposed 709,953 · Balance 2,913,070 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan. F2: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	14,194	Reported balance After 2022-04-04 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2022-04-04 · Other · Acquired 14,194 · Balance 14,194 F3: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII. F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2022-04-04 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2022-04-04 · Other · Disposed 14,194 · Balance 0 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners. F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	11,726	Reported balance After 2022-04-04 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2022-04-04 · Other · Acquired 11,726 · Balance 11,726 F6: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP. F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2022-04-04 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2022-04-04 · Other · Disposed 11,726 · Balance 0 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members. F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,863,197	Reported balance Holding disclosure · report date 2022-04-04 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,863,197 F9: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	552,149	Reported balance Holding disclosure · report date 2022-04-04 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 552,149 F10: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan.

F2: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

F3: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII.

F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners.

F6: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP.

F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members.

F9: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

F10: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 16, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	177	$33.01	$5,843.21	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937,632 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 16, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	23	$33.01	$759.29	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 984,669 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 13, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,502	$34.53	$51,865.41	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937,809 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $34.715, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 13, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	2,473	$33.31	$82,387.75	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,939,311 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 13, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	198	$34.53	$6,837.12	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 984,692 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $34.715, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 13, 2020 Filed Nov 17, 2020 19:33 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	327	$33.31	$10,893.97	Disclosure SEC source: 0000899243-20-031322 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 984,890 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	353	$35.15	$12,407.53	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 16 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,941,784 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (21) to this Form 4. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	9,450	$34.39	$325,011.96	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 15 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,942,137 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (20) to this Form 4. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	3,976	$33.48	$133,106.14	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 14 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,951,587 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (18) to this Form 4. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	47	$35.15	$1,651.99	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 13 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 985,217 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (21) to this Form 4. F19 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,248	$34.39	$42,922.21	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 12 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 985,264 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (20) to this Form 4. F19 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 12, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	524	$33.48	$17,542.16	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 11 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 986,512 F17 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (18) to this Form 4. F19 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	9,027	$34.94	$315,378.10	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646,377 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.40 to $35.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	2,119	$33.86	$71,748.49	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,655,404 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.36 to $34.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,191	$34.94	$41,610.21	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 987,036 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.40 to $35.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	280	$33.86	$9,480.69	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 988,227 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.36 to $34.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	4,282	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 10 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners. F12 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	3,211	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 9 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,282 F15 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel. F12 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	59,534	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 427,063 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners. F14 · ownership.nature: Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	1,071	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,071 F11 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I. F12 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	199,652	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,432,212 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners. F10 · ownership.nature: Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. Bradley J. Bolzon may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	11,918	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	11,918	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,918 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	13,816	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	13,816	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,816 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:47 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	OtherCommon Stock	690,814	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031061 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,955,563 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI"), to its partners. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	12,433	$34.14	$424,509.87	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,657,523 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	11,388	$33.48	$381,245.19	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,669,956 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,642	$34.14	$56,064.12	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 988,507 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:41 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,503	$33.48	$50,317.13	Disclosure SEC source: 0000899243-20-030855 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 990,149 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 09, 2020 Filed Nov 10, 2020 19:24 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	5,565	$33.06	$183,954.41	Disclosure SEC source: 0000899243-20-030745 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,681,344 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 09, 2020 Filed Nov 10, 2020 19:24 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	735	$33.06	$24,295.87	Disclosure SEC source: 0000899243-20-030745 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 991,652 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 06, 2020 Filed Nov 10, 2020 19:24 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	2,738	$33.13	$90,705.83	Disclosure SEC source: 0000899243-20-030745 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,686,909 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 06, 2020 Filed Nov 10, 2020 19:24 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	362	$33.13	$11,992.52	Disclosure SEC source: 0000899243-20-030745 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 992,387 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 05, 2020 Filed Nov 6, 2020 16:44 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	7,816	$33.15	$259,079.30	Disclosure SEC source: 0000899243-20-030580 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,689,647 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 05, 2020 Filed Nov 6, 2020 16:44 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,032	$33.15	$34,208.01	Disclosure SEC source: 0000899243-20-030580 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 992,749 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 04, 2020 Filed Nov 6, 2020 16:44 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	2,208	$33.14	$73,163.63	Disclosure SEC source: 0000899243-20-030580 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697,463 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
November 04, 2020 Filed Nov 6, 2020 16:44 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	292	$33.14	$9,675.62	Disclosure SEC source: 0000899243-20-030580 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 993,781 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 27, 2020 Filed Oct 28, 2020 17:58 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	707	$33.03	$23,353.98	Disclosure SEC source: 0000899243-20-029546 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,699,671 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 27, 2020 Filed Oct 28, 2020 17:58 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	93	$33.03	$3,072.02	Disclosure SEC source: 0000899243-20-029546 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 994,073 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 26, 2020 Filed Oct 28, 2020 17:58 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	7,158	$33.30	$238,394.33	Disclosure SEC source: 0000899243-20-029546 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700,378 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 26, 2020 Filed Oct 28, 2020 17:58 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	945	$33.30	$31,472.85	Disclosure SEC source: 0000899243-20-029546 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 994,166 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 19, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	3,739	$33.43	$124,998.14	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,707,536 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 19, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	494	$33.43	$16,514.86	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 995,111 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 16, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	7,697	$33.57	$258,409.84	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,711,275 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 16, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	1,016	$33.57	$34,109.96	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 995,605 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 15, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	2,473	$33.03	$81,693.82	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,718,972 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 15, 2020 Filed Oct 20, 2020 20:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	327	$33.03	$10,802.22	Disclosure SEC source: 0000899243-20-028811 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 996,621 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 14, 2020 Filed Oct 15, 2020 19:22 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	4,859	$33.09	$160,787.23	Disclosure SEC source: 0000899243-20-028366 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,721,445 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 14, 2020 Filed Oct 15, 2020 19:22 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	SaleCommon Stock	642	$33.09	$21,244.17	Disclosure SEC source: 0000899243-20-028366 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 996,948 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.